Patents
Literature
Patsnap Eureka AI that helps you search prior art, draft patents, and assess FTO risks, powered by patent and scientific literature data.

108 results about "Methyltransferase" patented technology

Methyltransferases are a large group of enzymes that all methylate their substrates but can be split into several subclasses based on their structural features. The most common class of methyltransferases is class I, all of which contain a Rossman fold for binding S-Adenosyl methionine (SAM). Class II methyltransferases contain a SET domain, which are exemplified by SET domain histone methyltransferases, and class III methyltransferases, which are membrane associated. Methyltransferases can also be grouped as different types utilizing different substrates in methyl transfer reactions. These types include protein methyltransferases, DNA/RNA methyltransferases, natural product methyltransferases, and non-SAM dependent methyltransferases. SAM is the classical methyl donor for methyltrasferases, however, examples of other methyl donors are seen in nature. The general mechanism for methyl transfer is a SN2-like nucleophilic attack where the methionine sulfur serves as the nucleophile that transfers the methyl group to the enzyme substrate. SAM is converted to S-Adenosyl homocysteine (SAH) during this process. The breaking of the SAM-methyl bond and the formation of the substrate-methyl bond happen nearly simultaneously. These enzymatic reactions are found in many pathways and are implicated in genetic diseases, cancer, and metabolic diseases.

CuCCoAOMT1 gene of Chimonobambusa auriculata, and protein and application of CuCCoAOMT1 gene

The invention discloses a Chimonobambusa chensinensis CuCCoAOMT1 gene as well as a protein and application thereof, belongs to the technical field of plant genetic engineering, and particularly relates to a Chimonobambusa chensinensis caffeoyl-coenzyme A-O-methyltransferase CuCCoAOMT1 gene, and a nucleotide sequence of the CuCCoAOMT1 gene is shown as SEQ ID NO.1. The invention further discloses a preparation method of the CuCCoAOMT1 gene. The invention further discloses application of the CuCCoAOMT1 gene in regulation and control of the drought resistance of gramineous plants. By overexpressing the caffeoyl-coenzyme A-O-methyltransferase CuCCoAOMT1 gene in the rice, the lignin content in the rice can be effectively increased, the thickening of rice cell walls is promoted, the drought resistance of rice plants is improved, and a new gene resource is provided for plant material property improvement gene engineering.
Owner:INT CENT FOR BAMBOO & RATTAN

Serine hydroxymethyltransferase mutant and application thereof in production of L-serine

PendingCN121628869ABacteriaTransferasesEscherichia coliFormaldehyde synthesis
The invention discloses a serine hydroxymethyltransferase mutant and an application thereof in production of L-serin.The serine hydroxymethyltransferase mutant with the specific enzyme activity remarkably improved is obtained by conducting saturated mutation on serine hydroxymethyltransferase from escherichia coli and conducting screening, and the serine hydroxymethyltransferase mutant is applied to synthesis of L-serine. The serine hydroxymethyltransferase disclosed by the invention can be used for effectively improving the efficiency of catalyzing glycine and formaldehyde to synthesize L-serine by using the serine hydroxymethyltransferase, reducing the enzyme dosage, remarkably reducing the production cost and reducing the separation difficulty of downstream products.
Owner:HENAN ZHONGYUAN YUZE BIOTECHNOLOGY CO LTD

Artificial efficient nitrogen fixation system as well as preparation method and application thereof

The invention relates to an artificial efficient nitrogen fixation system and a preparation method and application thereof. The artificial efficient nitrogen fixation system contains recombinant engineering bacteria constructed by an artificial combination module and nitrogen fixation chassis microorganisms; wherein the artificial combination module sequentially comprises a constitutive promoter element Pc and a coding gene of methyltransferase selected from nitrogen-fixing pseudomonas stutzeri A1501 in the direction from upstream to downstream. According to the recombinant engineering bacteria constructed by introducing the artificial combination module into the nitrogen-fixing chassis microorganism, the nitrogenase activity of the nitrogen-fixing chassis microorganism can be remarkably improved, the nitrogen-fixing capacity of the nitrogen-fixing chassis microorganism is remarkably improved, and the recombinant engineering bacteria have a relatively good application prospect in the aspect of promoting plant growth.
Owner:THE INST OF BIOTECHNOLOGY OF THE CHINESE ACAD OF AGRI SCI

Methyltransferase mutant and its application in production of icariin

The application provides a methyltransferase mutant and application thereof in production of icariin, and belongs to the technical field of bioengineering. The application solves the problem of low icariin yield in the prior art. The methyltransferase mutant is obtained by mutating any one of the 76th position, the 146th position, the 250th position and the 290th position of the amino acid shown in SEQ ID NO. 2. The methyltransferase mutant is mainly used for efficient methyltransferase and application thereof in synthesis of icariin.
Owner:QINHUANGDAO HUIEN BIOTECHNOLOGY CO LTD

Method for regulating and controlling fish skeletal development through runx2b promoter methylation editing and application thereof

The invention belongs to the technical field of biology, and particularly relates to a construction method of epigenome edited zebrafish, sgRNA of a targeted zebrafish runx2b gene promoter region and application of the sgRNA. The invention provides a construction method of epigenome edited zebrafish, which comprises the step of carrying out methylation editing by using a CRISPR / dCas9-methyltransferase system targeting runx2b gene promoter region, thereby inhibiting runx2b gene expression and reducing intermuscular bone formation. According to the method, the expression level of the runx2b gene is accurately regulated and controlled through an epigenetic editing technology on the premise that a DNA sequence is not changed, and formation of fish intermuscular bones is effectively reduced. The zebra fish F0 treated by the method represents that the runx2b mRNA expression level is obviously reduced, and the intermuscular bones of the eleventh to sixteenth sarcomedo regions of adult F0 generation fish are obviously shorter than those of a control group, and the shortening range reaches 23.3% to 38.8%. Besides, the method provides theoretical basis and technical support for improving fish economic traits by accurately regulating and controlling the expression mode of the key economic trait gene and simultaneously keeping the integrity of genome DNA (Deoxyribose Nucleic Acid).
Owner:SOUTH CHINA NORMAL UNIV

A method for biologically preparing fluorinated phenoxazines and derivatives thereof and applications thereof

This invention discloses a method for the biosynthesis and application of fluorinated phenazine and its derivatives, belonging to the field of bioengineering technology. The invention aims to provide a method for synthesizing fluorinated phenazine and its derivatives. Specifically, it provides an in vitro enzyme cascade catalytic reaction method for synthesizing fluorinated phenazine and its derivatives, in which halogenated methyltransferase HMT1 and O-methyltransferase LaphzM, or halogenated methyltransferase HMT1 and N-methyltransferase PhzM, are added to a reaction buffer containing 1-hydroxyphenazine and its derivatives to obtain fluorinated phenazine and its derivatives. The enzyme concentrations of halogenated methyltransferase HMT1 and O-methyltransferase LaphzM are 2:1; the enzyme concentrations of halogenated methyltransferase HMT1 and N-methyltransferase PhzM are 2:1. This establishes a pathway for the synthesis of fluorinated phenazine from 1-hydroxyphenazine and its derivatives, providing a new approach for the biosynthesis of fluorinated phenazine.
Owner:SHANDONG UNIV OF TECH

Methods for quantitative monitoring of mRNA capping efficiency

This invention relates to a method for quantifying mRNA capping efficiency, the method comprising mixing a sample, an enzyme mixture, and an isotope standard solution in a buffer solution to produce an incubation mixture, the enzyme mixture comprising a nonspecific single-stranded nuclease and an acid phosphatase, and the isotope standard comprising isotopically labeled m7G and isotopically labeled 2'-O-methylated nucleoside; incubating the mixture; and analyzing the mixture using liquid chromatography-mass spectrometry to determine at least one of capping efficiency and 2-O-methyltransferase efficiency.
Owner:THERMO FINNIGAN LLC

Genetically engineered bacterium for synthesizing melatonin and application of genetically engineered bacterium

The invention relates to the field of genetic engineering and fermentation engineering, and discloses a genetically engineered bacterium for producing melatonin and application of the genetically engineered bacterium in fermentation production of melatonin. According to the invention, genes of mtrA, PTPS, SPR, PCD and DHPR of related enzymes synthesized by coding 2-amino-6-(1, 2-dihydroxypropyl)-5, 6, 7, 8-tetrahydro-4 (1H)-pterin diketone and genes of L-2-amino-3 (beta-indole) propionic acid monooxygenase, oxymethyltransferase, N-acetyltransferase and decarboxylase are co-expressed on the genetically engineered bacterium, so that the gene engineering bacterium is obtained. The strain can be used for fermentation production of melatonin, and experiments show that the yield of the strain can reach 6480 mg / L.
Owner:TIANJIN INST OF IND BIOTECH CHINESE ACADEMY OF SCI

Method for producing Labyrinthula microorganisms and sterol esters

PendingJP2026115641AMicroorganismSterol ester
The object of this invention is to provide Labyrinthula microorganisms that have high sterol ester production capacity. [Solution] A Labyrinthull microorganism modified to have reduced or lost activity of sterol 24-C-methyltransferase (SMT1) compared to an unmodified strain, wherein the Labyrinthull microorganism is modified to express a modified diacylglycerol acyltransferase 2C (modified DGAT2C) gene, and the modified diacylglycerol acyltransferase 2C (modified DGAT2C) is modified to have a defect in presumed transmembrane regions 1 to 8 of the presumed transmembrane regions 1 to 12 in diacylglycerol acyltransferase 2C (DGAT2C).
Owner:KYUSHU UNIV +1

Composition for promoting expression of glycine-n-methyltransferase

The invention provides a composition containing a white peony root extract, a Chinese magnoliavine fruit extract, a pomegranate extract and a ginseng extract. The composition or the nutritional supplement and the pharmaceutical composition containing the composition can obviously promote the expression of the individual glycine-N-methyltransferase, so that the composition can be applied to nutritional supplement or pharmaceutical products for resisting aging, fatty liver or liver cancer and the like.
Owner:THE ONE BIOPHARMACEUTICAL CO LTD

Preparation method of irisflorentin

PendingCN121801985ABacteriaTransferasesS-Adenosyl-l-methionineBelamcanda chinensis
The invention relates to a method for preparing irisflorentin by utilizing belamcandin, and belongs to the technical field of biology. The method comprises the following steps: carrying out C-5 site and C-3'site methylation reaction by taking white belamcandin as a substrate, taking belamcanda methyl transferase gene BcOMT03 gene encoding protein and belamcanda methyl transferase BcOMT33 gene encoding protein as catalysts and taking S-adenosine-methionine as a methyl donor to generate a corresponding glycosylation product. According to the invention, the functions of the two methyltransferase genes BcOMT03 and BcOMT33 in the blackberry lily are identified and verified for the first time, the effect of the two methyltransferase genes BcOMT03 and BcOMT33 in catalyzing the ibullamcandin to produce the irisflorentin is defined, and the blank of research on the biosynthetic pathway of the characteristic component irisflorentin of the blackberry lily is filled up; important information is provided for research on a biosynthesis mechanism of active ingredients of medicinal plants.
Owner:YUNNAN AGRICULTURAL UNIVERSITY

A gain-of-function mutation in poxvirus encoded 2'o-methyltransferase: enhancing stability and translational efficiency of viral mRNA

The present invention is related to method of preparing a gain-of-function mutation in poxvirus, like buffalopox virus (BPXV) by long-term propagating it in the presence of methyltransferase inhibitor like 3-Deazaneplanocin A (DZNep), which results in generation of viral 2'O-MTAse (VP39) mutant with a single point mutation (M236I). The resultant mutant has the following characteristics: (a) M236I mutation of 2'O-MTAse increases the cap-1 markings on viral mRNA; (b) The 2'O-MTAse mutant virus had hyperactive 2'O-MTAse and exhibited enhanced stability and translational efficiency of its mRNA; (c) The capping (cap1) performed by the mutant viral 2'O-MTAse (VP39) results in higher viral protein production, as compared to the wild type VP39 and (d) Mutant virus replicated at higher viral titer than the wild-type virus.
Owner:ICAR-NAT RES CENT ON EQUINES

Polyheterocyclic compounds as mettl3 inhibitors

METTL3 (N6 Adenosine Methyltransferase 70kDa Subunit) To provide an inhibitor of enzyme activity.SOLUTION: For example, N - ({2 - [(4, 4-dimethylpiperidin-l-yl) methyl] - 1H - indol-6-yl} methyl) - 4-oxo - 4H - pyrido [l, 2-a] pyrimidine-2-carboxamide is shown to have the following structure. The invention also relates to processes for the preparation of these compounds, to pharmaceutical compositions containing them and to their use in the treatment of proliferative disorders such as cancers and auto-immune diseases and other diseases or conditions in which METTL3 activity is implicated.SELECTED DRAWING: None
Owner:STORM THERAPEUTICS LIMITED

A monkeypox virus n7-methyltransferase inhibitor high-throughput screening method based on fluorescence polarization technology and application

This invention discloses a high-throughput screening method for monkeypox virus (MPXV) N7-methyltransferase (N7-MTase) inhibitors based on fluorescence polarization technology and its application. This method uses MPXV E1... CTD Using the / E12 protein complex as a target, and leveraging the specific binding characteristic of the fluorescent probe FL-NAH to the target catalytic center, small molecule inhibitors that competitively bind to the SAM binding site are screened by monitoring changes in fluorescence polarization signals. This invention yielded a series of candidate compounds with significant inhibitory activity. Experiments demonstrated that these inhibitors exhibit strong inhibitory effects on MPXV N7-MTase, with a biochemical IC50 level of [missing information]. 50 Preferably, the concentration can reach 4.65 μM; at the cellular level, the compound exhibits a clear attenuation effect against poxviruses, with an EC50 value of [missing value]. 50 The range is up to 46.75 μM, and it has low cytotoxicity (CC). 50 >200 μM).
Owner:ZHEJIANG UNIV

A gene overexpression vector and gene expression strategy for non-model b. laterosporus

This invention discloses a plasmid for gene overexpression in non-pattern *Bacillus laterosporus*. Its leader region contains a methyltransferase expression cassette derived from the *Bacillus laterosporus* i83 genome, enabling stable existence in specific hosts containing the RM system. Based on this, a PidR2 promoter is added to obtain the pMCPidR2 shuttle plasmid. The PidR2 promoter effectively drives target gene expression, the pWV01 replicon ensures plasmid replication in non-pattern hosts, and the chloramphenicol resistance gene is used for positive colony selection. The plasmid contains a TraJ element, allowing it to be introduced into non-pattern microbial hosts via conjugation transfer. This invention also provides a target gene expression strategy in non-pattern microorganisms, achieving high transformation efficiency and high strain yield through conjugation transfer transformation of donor bacteria, conjugation transfer helper bacteria, and recipient bacteria, resulting in stable expression of the target protein. This invention provides an effective vector for efficient and stable gene overexpression in specific non-pattern microorganisms, helping to solve the problem of difficult genetic manipulation of industrial production strains.
Owner:CHONGQING ACAD OF ANIMAL SCI +1

Peptide inhibitors targeting methyltransfer mechanism of SARS-CoV-2

Synthetic peptides mimicking the nsp10 sequence in the region interacting with nsp16 capable of penetrating cell membranes and inhibiting SARS-CoV-2 replication for the treatment of moderate to severe COVID-19. The invention relates to peptides inhibiting SARS-CoV-2 replication, likely through inhibition of Methyltransferase complexes (NSP10 / NSP16 and NSP10 / NSP14). The peptide of the present invention, P3, contains sequences corresponding to amino acids 89-96 of the non-structural protein 10 (NSP10) of SARS-CoV-2, with the only Cysteine modified to a Methionine. This peptide was made based on two previous designs P1 and P2, which constituted the amino acids 68-96 of the NSP10 protein of SARS-CoV-2.
Owner:UNITED ARAB EMIRATES UNIVERSITY

Application of METTL5 as a tumor immunotherapy targeting site

ActiveCN115998875BPeptide/protein ingredientsAntineoplastic agentsBase JAntineoplastic Immunotherapeutic
The application relates to the technical field of tumor drugs, in particular to application of METTL5 as a tumor immunotherapy targeting site. The base sequence of the METTL5 is shown in SEQ ID No. 1; wherein the METTL5 is a brand-new RNAm6A methyltransferase, is closely related to ribosome translation function, and can regulate the translation of a tumor immune key regulator IL-27; therefore, the METTL5 is used as the tumor immunotherapy targeting site, the expression of the METTL5 related genes or coding proteins is inhibited through targeting, the body anti-tumor immunity can be effectively stimulated, the METTL5 becomes the targeting site capable of enhancing the response rate of tumor immunotherapy, and the METTL5 used as the tumor treatment target point has a wide application prospect in the anti-tumor immunotherapy.
Owner:SOUTHERN UNIVERSITY OF SCIENCE AND TECHNOLOGY

Methods for detecting chromatin accessibility or DNA-binding protein footprints in cells based on a two-enzyme approach

The present invention belongs to the field of biotechnology. In particular, the present invention relates to a method for detecting chromatin accessibility or DNA binding protein footprint in cells based on a two-enzyme method. More specifically, the present invention relates to a method for converting information on the openness of chromatin into information on mutations in DNA sequences by means of adenine methyltransferase and adenine deaminase, thereby quantitatively determining the chromatin accessibility of DNA molecules and the binding footprint of DNA binding proteins, such as transcription factors.
Owner:SHANGHAI TONGJI HOSPITAL +1

Astragalus root calyx heterophylla methyltransferase protein AmOMT1, coding gene, primer set and application thereof

The application provides a astragalus membranaceus calyx heterophylla isoflavone methyltransferase protein AmOMT1, a coding gene, a primer set and application thereof, and belongs to the technical field of biotechnology.The amino acid sequence of the astragalus membranaceus calyx heterophylla isoflavone methyltransferase protein AmOMT1 is shown as SEQ ID No.1.Based on astragalus membranaceus genomic and second-generation transcriptomic data, a methyltransferase AmOMT1 with 4' and 7 position methylation functions for 3', 4', 7-trihydroxyisoflavone is found and identified by a reverse genetics method.Experiments show that AmOMT1 can catalyze the methylation of 3', 4', 7-trihydroxyisoflavone to generate calyx heterophylla isoflavone and 3', 4'-dihydroxy-7-methoxyisoflavone.
Owner:INSTITUTE OF CHINESE MATERIA MEDICA CHINA ACADEMY OF CHINESE MEDICAL SCIENCES

A demethylmenaquinone methyltransferase mutant, its construction method and application

PendingCN122081263ABacteriaTransferasesVitamin K2Metabolic network
This invention discloses a desmethylmenoprenone methyltransferase mutant, its construction method, and its applications, belonging to the field of biotechnology. Desmethylmenoprenone methyltransferase is a key enzyme in the MK-7 biosynthetic pathway, responsible for catalyzing the methylation reaction of desmethylmenoprenone to generate a series of methylnaphthoquinone (MK) products, ultimately forming MK-7. This invention, through metabolic network regulation and rational design, successfully obtained 19 single-point mutants, among which 5 mutants showed significantly higher catalytic efficiency than the wild-type enzyme. Experimental results show that the recombinant engineered bacteria constructed based on these mutants exhibit significant advantages in the whole-cell catalytic production of vitamin K2 (MK-7), with MK-7 yield increased by more than 20% compared to the wild-type strain. The excellent catalytic performance of the menG mutant provided by this invention provides strong technical support for the industrial production of vitamin K2, and has broad application prospects and market value.
Owner:SUZHOU ZHIYUAN CHUANGLIAN BIOTECHNOLOGY CO LTD

A high-throughput screening method for phenylethanolamine n-methyltransferase

The application discloses a high-throughput screening method of phenylethanolamine-N-methyltransferase. Substrate norepinephrine and S-adenosyl methionine, PBS buffer, S-adenosyl-L-homocysteine hydrolase SAHH are added in a 96-well plate of a microplate reader, enzyme sample phenylethanolamine-N-methyltransferase is added, in a microplate shaking reactor, 20-50 DEG C, 500-1000 rpm, reaction for 1-3 h, 4 DEG C, 3700 rpm centrifugation, the supernatant is taken, compound NDCC is added again, reaction for 0-90 min, during the reaction, the microplate is taken out every 1-30 min, and the microplate reader is used to detect the absorbance value; according to the absorbance value change, the enzyme activity is defined as the change of OD405nm absorbance value per minute * 1000000 under specific conditions. The application has the characteristics of simple operation, low cost and accurate detection, and has far-reaching significance for the directed evolution of phenylethanolamine-N-methyltransferase.
Owner:NANJING TECH UNIV

Broad spectrum anti-cancer compounds

ActiveUS12630527B2Sugar derivativesAntineoplastic agentsAntisense nucleic acidMethyltransferase
Described herein, inter alia, are compounds for treating cancer and methods of use. This disclosure features chemical entities (e.g., small hairpin RNAs (shRNAs), micro RNA (miRNAs), small interfering RNA (siRNAs), small molecule inhibitors, antisense nucleic acids, peptides, viruses, CRISPR-sgRNAs, or combinations thereof) that inhibit one or more of m6A writers (e.g., methyltransferase like 3 (Mettl3 or MT-A70) or methyltransferase like-14 (Mettl14)), m6Am writers (e.g., phosphorylated CTD interacting factor I (PCIF 1), or Mettl3 / 14), m6A erasers (e.g., fat-mass and obesity-associated protein (FTO) or ALKB homolog 5 (ALKBH5)), m6Am erasers (e.g., FTO), m6A readers (e.g., YTH domain-containing family proteins (YTHs)), YTF domain family member 1 (YTHDF 1), YTF domain family member 2 (YTHDF 2), YTF domain family member 3 (YTHDF 3), or tyrosine-protein phosphatase non-receptor type 2 (PTPN2).
Owner:RGT UNIV OF CALIFORNIA

Application of rice RNA adenine methyltransferase gene in regulating plant resistance to virus

PendingCN122303292ABiotechnologyMutant
This invention belongs to the field of plant biocontrol. Specifically, this invention provides the application of the rice RNA adenine methyltransferase EDM2L gene in regulating plant antiviral resistance. This was achieved by comparing rice plants inoculated with RSV virus. edm2l Knockout mutants and edm2l' Analysis of methyltransferase catalytic activity mutants and ZH11 wild plants revealed that knockout edm2l Downregulation of EDM2L expression significantly weakens rice's resistance to RSV, indicating that this gene has an anti-RSV function. This invention provides a new target gene locus for cultivating crops with enhanced virus resistance using genetic engineering techniques, and has significant implications and broad application prospects in regulating plant resistance and disease-resistant breeding.
Owner:INST OF ZOOLOGY CHINESE ACAD OF SCI

Application of PWWP2B as a target in the preparation of drugs for the treatment of leukemia

This invention relates to the application of PWWP2B as a target in the preparation of drugs for the treatment of leukemia, belonging to the field of biomedical technology. To address the problem that traditional AML treatment targets lack tumor specificity and fail to meet clinical needs, this invention provides the application of PWWP2B as a target in the preparation of drugs for the treatment of leukemia. This invention demonstrates that PWWP2B is highly expressed in acute myeloid leukemia (AML) cells, and as a molecular marker, it can accurately distinguish AML from healthy individuals or non-leukemia patients. In vivo and in vitro experiments demonstrate that knocking out PWWP2B can significantly inhibit the proliferation and colony formation of AML cells, promote their differentiation and apoptosis, and inhibit the activity of leukemia cells in patients. This invention also reveals for the first time a novel use of the small molecule compound EZM0414 in the treatment of AML and its synergistic effect when used in combination with methyltransferase inhibitors.
Owner:HARBIN MEDICAL UNIVERSITY

Carbon-methyltransferase and application thereof

The invention relates to a carbon-methyltransferase (RdCMT) and an application of the carbon-methyltransferase (RdCMT) in synthesis of farrerol. RdCMT is cloned and is subjected to heterologous expression in Escherichia coli BL21 (DE3) by mining transcriptome information of Rhododendron dauricum, the generated fusion protein of which the N terminal or / and the C terminal are / is connected with tags can specifically and efficiently catalyze C-3 'and C-5' methylation of chalcone compounds naringenin chalcone to generate a double-carbon-methylation product, and the double-carbon-methylation product is spontaneously dehydrated to generate the farrerol. The invention also relates to the application of the RdCMT in a model plant Nicotiana benthamiana, and the production of the farrerol through the construction of a total synthesis path of the Nicotiana benthamiana.
Owner:PEKING UNIV

A protein for generating methyl anthranilate, an aroma component of tea leaves, and a gene and application thereof

The application belongs to the technical field of biological gene engineering, and particularly relates to a protein for generating methyl o-aminobenzoate, a gene thereof and application. S A protein for generating methyl o-aminobenzoate from adenosylmethionine and o-aminobenzoate, wherein the amino acid sequence of the protein is shown as SEQ ID NO. 2. The experiment of the application proves that methyl o-aminobenzoate methyltransferase CsAAMT is found in a new tea variety 'Zhongchaxiangning', the gene corresponding to the protein is expressed in Escherichia coli, and the purified recombinant protein has the activity of catalyzing S o-aminobenzoate from adenosylmethionine and o-aminobenzoate, and further, the tea leaves without the aroma component can release methyl o-aminobenzoate by transiently overexpressing the gene in tea leaves.
Owner:TEA RESEARCH INSTITUTE CHINESE ACADEMY OF AGRICULTURAL SCIENCES

Inhibitors for protein n-terminal methyltransferase and uses thereof

The present invention relates to series of peptidomimetic compounds as an inhibitor targeting protein N-terminal methyltransferase pharmacological pathway. Pharmaceutical compositions of those compounds and methods of using them in the treatment of diseases caused by abnormal protein methyltransferase pathway, including cancer, inflammation, neurodegenerative and cardiovascular diseases, are within the scope of this disclosure.
Owner:PURDUE RES FOUND

Controllable RNA m6a demethylation editing system and application thereof

PendingCN122349560ANormal cellInducer
Provided is a controllable RNAm6A demethylation editing system comprising a targeting element and an editing element. The targeting element comprises an inactivated Cas13 protein, and the editing element comprises a methyltransferase domain of FTO and / or ALKBH5. The editing system can specifically perform m6A demethylation editing in tumor cells without affecting the m6A demethylation regulation of normal cells. In addition, the editing system does not require additional light or chemical inducers, thereby eliminating the side effects of inducers on cells and organisms.
Owner:SUZHOU MERNA THERAPEUTICS CO LTD

Inhibitors for protein n-terminal methyltransferase and uses thereof

The present invention relates to series of peptidomimetic compounds as an inhibitor targeting protein N-terminal methyltransferase pharmacological pathway. Pharmaceutical compositions of those compounds and methods of using them in the treatment of diseases caused by abnormal protein methyltransferase pathway, including cancer, inflammation, neurodegenerative and cardiovascular diseases, are within the scope of this disclosure.
Owner:PURDUE RES FOUND

Tetrahydrofolate methyltransferase mutant, gene encoding same and use thereof

PCT designated stageWO2026091465A1BacteriaTransferasesTetrahydrofolic acidMutant
A tetrahydrofolate methyltransferase mutant, a gene encoding same and the use thereof. Provided is a tetrahydrofolate methyltransferase RcoDmdA mutant, which has an amino acid sequence as represented by SEQ ID NO. 3. The RcoDmdA mutant has higher catalytic activity. The substrate THF feeding amount is significantly increased to 15-20 g / L, the yield of product L-5-MTHF is increased to 15-17 g / L, and the substrate conversion rate is high. The tetrahydrofolate methyltransferase mutant and the gene encoding same have great value for industrial application.
Owner:ZHEJIANG SHENGDA BIO PHARM +2